StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)

Close on Nov 17, 2026Market cap $151.09MP/E –Yield –

Invivyd r&d expenses

Research and development expenses are spending on new products and technology.

Invivyd's R&D Expenses for the twelve months ending Jun 30, 2026 was $78.19M, down 18.5% year over year. For fiscal 2025 it was $38.31M, down 72.1% from the year before. The highest annual figure on record is $182.89M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$38.31M-72.1%
FY2024Dec 31, 2024$137.25M-13.5%
FY2023Dec 31, 2023$158.66M-11.5%
FY2022Dec 31, 2022$179.21M-2.0%
FY2021Dec 31, 2021$182.89M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.37M+206.8%
Q1 FY2026Mar 31, 2026$30.73M+188.8%
Q4 FY2025Dec 31, 2025$10.05M-43.9%
Q3 FY2025Sep 30, 2025$8.05M-86.1%
Q2 FY2025Jun 30, 2025$9.57M-68.4%
Q1 FY2025Mar 31, 2025$10.64M-65.9%
Q4 FY2024Dec 31, 2024$17.91M-71.2%
Q3 FY2024Sep 30, 2024$57.85M+126.2%
Q2 FY2024Jun 30, 2024$30.33M-30.5%
Q1 FY2024Mar 31, 2024$31.16M+14.6%
Q4 FY2023Dec 31, 2023$62.27M+212.6%
Q3 FY2023Sep 30, 2023$25.57M-15.1%
Q2 FY2023Jun 30, 2023$43.62M+17.5%
Q1 FY2023Mar 31, 2023$27.20M-70.4%
Q4 FY2022Dec 31, 2022$19.92M-70.9%
Q3 FY2022Sep 30, 2022$30.13M-33.6%
Q2 FY2022Jun 30, 2022$37.13M+5.9%
Q1 FY2022Mar 31, 2022$92.04M+170.4%
Q4 FY2021Dec 31, 2021$68.43M+843.7%
Q3 FY2021Sep 30, 2021$45.37M–
Q2 FY2021Jun 30, 2021$35.07M–
Q1 FY2021Mar 31, 2021$34.03M–
Q3 FY2020Sep 30, 2020$7.25M–

More Invivyd figures

See a number that looks wrong?